弥漫性大B细胞淋巴瘤患者的治疗策略：过去、现在与未来
Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future.
作者信息
Sinha Rajni, Nastoupil Loretta, Flowers Christopher R
机构信息
Department of Hematology/Medical Oncology, Winship Cancer Institute, 1365 C Clifton Road, Ste 4005, Atlanta, GA 30322, Office: 404-778-1827.
出版信息
Blood Lymphat Cancer. 2012 Apr 19;2012(2):87-98. doi: 10.2147/BLCTT.S18701.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. DLBCL is a clinically, biologically, and pathologically heterogeneous entity with biologically distinct subtypes that have different expected treatment outcomes. The addition of rituximab to combination chemotherapy has improved outcomes for all patients with DLBCL and can produce cure for many individuals. Relapsed DLBCL is generally managed with salvage chemo-immunotherapy followed by high dose therapy and autologous stem cell transplantation which can cure additional patients. However, outcomes for patients who relapse early after upfront rituximab and chemotherapy have a poorer prognosis. Novel therapies and strategies are desperately needed for these patients and several emerging treatments hold promise for improving DLBCL treatment outcomes in the future.
摘要
弥漫性大B细胞淋巴瘤（DLBCL）是西方世界最常见的淋巴瘤。DLBCL是一种临床、生物学和病理学上异质性的实体，具有生物学上不同的亚型，其预期治疗结果也不同。在联合化疗中加入利妥昔单抗改善了所有DLBCL患者的治疗结果，并且可以治愈许多患者。复发的DLBCL通常采用挽救性化学免疫疗法，随后进行高剂量治疗和自体干细胞移植，这可以治愈更多患者。然而，在 upfront 利妥昔单抗和化疗后早期复发的患者预后较差。这些患者迫切需要新的治疗方法和策略，一些新兴治疗方法有望在未来改善DLBCL的治疗结果。
相似文献
1
Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future.
Blood Lymphat Cancer. 2012 Apr 19;2012(2):87-98. doi: 10.2147/BLCTT.S18701.
2
Accelerated therapeutic progress in diffuse large B cell lymphoma.
Ann Hematol. 2014 Apr;93(4):541-56. doi: 10.1007/s00277-013-1979-7. Epub 2013 Dec 28.
3
Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient.
Immunotherapy. 2022 Jun;14(8):599-607. doi: 10.2217/imt-2021-0247. Epub 2022 Apr 20.
4
Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches.
Oncology (Williston Park). 2009 May;23(6):546-53.
5
Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
Cancer Med. 2021 Aug;10(15):5101-5109. doi: 10.1002/cam4.4062. Epub 2021 Jun 9.
6
Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):145-151. doi: 10.1016/j.clml.2016.11.001. Epub 2016 Nov 23.
7
Diffuse large B-cell lymphoma.
Crit Rev Oncol Hematol. 2013 Aug;87(2):146-71. doi: 10.1016/j.critrevonc.2012.12.009. Epub 2013 Jan 30.
8
A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial.
BMC Cancer. 2013 Jun 25;13:308. doi: 10.1186/1471-2407-13-308.
9
Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
Cancer. 2020 May 15;126(10):2279-2287. doi: 10.1002/cncr.32752. Epub 2020 Feb 12.
10
An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
Expert Rev Hematol. 2020 Sep;13(9):933-942. doi: 10.1080/17474086.2020.1795828. Epub 2020 Aug 10.
引用本文的文献
1
Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms.
Commun Biol. 2023 Mar 20;6(1):295. doi: 10.1038/s42003-023-04667-8.
2
RCHOP-14 therapy versus RCHOP-21 therapy for people with aggressive or advanced-stage indolent B-cell non-Hodgkins lymphoma: a systematic review and meta-analysis.
Transl Cancer Res. 2021 May;10(5):2044-2054. doi: 10.21037/tcr-20-3123.
3
Targeting Asparagine and Serine Metabolism in Germinal Centre-Derived B Cells Non-Hodgkin Lymphomas (B-NHL).
Cells. 2021 Sep 29;10(10):2589. doi: 10.3390/cells10102589.
4
Meta-analytical methods for estimating outcomes from overall response rate in patients with relapsed/refractory diffuse large B-cell lymphoma.
Oncotarget. 2019 May 14;10(35):3285-3293. doi: 10.18632/oncotarget.26904.
5
Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
Br J Haematol. 2017 Jul;178(1):72-80. doi: 10.1111/bjh.14638. Epub 2017 May 25.
6
Orbital MALT Lymphoma after Autologous Stem Cell Transplantation for Follicular Lymphoma as Relapse of Diffuse Large B-Cell Lymphoma.
J Clin Exp Hematop. 2017;56(3):170-175. doi: 10.3960/jslrt.56.170.
7
Prognostic Value of miRNA-155 Expression in B-Cell Non-Hodgkin Lymphoma.
Turk J Haematol. 2017 Aug 2;34(3):207-212. doi: 10.4274/tjh.2016.0286. Epub 2017 Feb 1.
8
Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis.
Haematologica. 2016 Nov;101(11):1380-1389. doi: 10.3324/haematol.2016.143891. Epub 2016 Jul 6.
9
B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease.
Expert Rev Hematol. 2016 Jun;9(6):553-61. doi: 10.1080/17474086.2016.1180972. Epub 2016 May 13.
10
To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes.
Curr Hematol Malig Rep. 2015 Sep;10(3):244-55. doi: 10.1007/s11899-015-0267-0.
本文引用的文献
1
Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States.
Cancer. 2011 Jun 1;117(11):2530-40. doi: 10.1002/cncr.25765. Epub 2010 Dec 22.
2
Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States.
Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):498-506. doi: 10.1016/j.clml.2011.07.002. Epub 2011 Sep 1.
3
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36. doi: 10.3322/caac.20121. Epub 2011 Jun 17.
4
Novel agents for diffuse large B-cell lymphoma.
Expert Opin Investig Drugs. 2011 May;20(5):669-80. doi: 10.1517/13543784.2011.565745. Epub 2011 Mar 28.
5
Incidence patterns and outcomes for hodgkin lymphoma patients in the United States.
Adv Hematol. 2011;2011:725219. doi: 10.1155/2011/725219. Epub 2010 Dec 16.
6
A decade of progress in lymphoma: advances and continuing challenges.
Clin Lymphoma Myeloma Leuk. 2010 Dec;10(6):414-23. doi: 10.3816/CLML.2010.n.086.
7
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.
J Clin Oncol. 2011 Jan 10;29(2):200-7. doi: 10.1200/JCO.2010.30.0368. Epub 2010 Dec 6.
8
Improving outcomes for patients with diffuse large B-cell lymphoma.
CA Cancer J Clin. 2010 Nov-Dec;60(6):393-408. doi: 10.3322/caac.20087. Epub 2010 Oct 28.
9
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.
Blood. 2010 Dec 2;116(23):4916-25. doi: 10.1182/blood-2010-03-276766. Epub 2010 Aug 24.
10
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
Cancer. 2010 Dec 1;116(23):5432-9. doi: 10.1002/cncr.25509. Epub 2010 Jul 27.
Zotero 插件